Person:
YOLDEMİR, AHMET TEVFİK

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

YOLDEMİR

First Name

AHMET TEVFİK

Name

Filters

20092
Reset filters

Settings

End date: 2009 × Start date: 2009 ×

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    PublicationMetadata only
    The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor- and hepatocyte growth factor in postmenopausal women
    (TAYLOR & FRANCIS LTD, 2009) YOLDEMİR, AHMET TEVFİK; Oezer, K. Sezer; Erenus, M.; Yoldemir, T.
    Objective To investigate the effect of tibolone and hormone treatment on serum C-reactive protein, tumor necrosis factor- and hepatocyte growth factor as independent markers of cardiovascular disease. Design Ninety-five normotensive and healthy postmenopausal women with no systemic or cardiac disease who attended the Marmara University Menopause Outpatient Clinic were included in this study. The women were assigned into three groups. The women who accepted hormone replacement therapy were randomized to two groups. Group 1 received 0.625mg conjugated estrogen (CE)+2.5mg medroxyprogesterone acetate (MPA)/day. Group 2 received 2.5mg tibolone/day. Group 3 was the control group consisting of women who did not want hormone replacement therapy. Serum samples were measured for highly specific C-reactive protein, tumor necrosis factor and hepatocyte growth factor before the treatment and after 6 months of therapy. Values at the end of the 6th month and baseline were compared. Results The increase in C-reactive protein and the decrease in tumor necrosis factor- levels demonstrated at the end of treatment were statistically significant, in both the hormone therapy and tibolone groups. However, the decrease in hepatocyte growth factor was significant only in the tibolone group. Conclusions The positive impact of both tibolone and hormone therapy on inflammatory markers appears to be protective against cardiovascular diseases. However, the clinical implications of these findings are yet to be evaluated in large clinical trials.
  • No Thumbnail Available
    PublicationMetadata only
    Assessment of bone mineral density should be considered earlier in perimenopausal women with vasomotor symptoms
    (WILEY, 2009) YOLDEMİR, AHMET TEVFİK; Tural, Alper; Yoldemir, Tevfik; Erenus, Mithat
    Objective: To investigate the relationship between vasomotor symptoms (hot flashes) and osteopenia or osteoporosis in perimenopausal women. Method: In this cross-sectional study 79 perimenopausal women aged between 45 and 55 years and seen at the Gynecology or Menopause Outpatient Clinic of Marmara University School of Medicine were allotted to one of 2 groups according to the presence or absence of hot flashes. The groups were then compared for bone mineral density (BMD) of the lumbar vertebrae, as measured by dual energy X-ray absorptiometry. Results: The mean BMD measurement for vertebrae L2 to L4 was 0.32 +/- 0.19 for the group with no hot flashes and -0.53 +/- 0.21 for the group with hot flashes (P = 0.007). In the former, 6.1% of the women and in the latter, 32.6% of the women had a BMD value less than a 1.5 standard deviation from the mean (P = 0.005). Conclusion: Women with vasomotor symptoms are more prone to have osteopenia or osteoporosis. (C) 2009 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved